Heron Therapeutics Inc. (HRTX) NASDAQ
$3.04 0.04 (1.17%)
Market Cap: $451.96M
As of 05/16/24 10:40 AM EDT. Market open.
Heron Therapeutics Inc. (HRTX)
NASDAQ
$3.04
0.04 (1.17%)
Market Cap: $451.96M
As of 05/16/24 10:40 AM EDT. Market open.
Add to Portfolio
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be ... read more
COMPANY PROFILE
Sector
Industry
CEO
Barry Quart
Full Time Employees
283
CEO Compensation (Base)
$614,414
CEO Compensation (Total)
$5.99M
Sector
Industry
CEO
Barry Quart
Full Time Employees
283
CEO Compensation (Base)
$614,414
CEO Compensation (Total)
$5.99M
URL
Address
4242 Campus Point Ct Ste 200, California, San Diego, 92121.
PRICE CHART FOR HERON THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$2.98
Previous Close
$3
Days Range
$2.80 - $3
52 week range
$0.50 - $3.22
Volume
1,315,978
Avg. Volume (30 days)
2,488,358
Market Cap
$451.96M
Dividend Yield
-
P/E
-
Shares Outstanding
150,653,158
Open
$2.98
Previous Close
$3
Days Range
$2.80 - $3
52 week range
$0.50 - $3.22
Volume
1,315,978
Avg. Volume (30 days)
2,488,358
Market Cap
$451.96M
Dividend Yield
-
P/E
-
Shares Outstanding
150,653,158
FINANCIAL STATEMENTS FOR HERON THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR HERON THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Duarte Ira | EVP, Chief Financial Officer | Apr 19, 2024 | Option Exercise | $2.64 | 1,122 | 2,962 | 87,752 | Apr 19, 2024, 05:48 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jan 13, 2024 | Option Exercise | $2.15 | 756 | 1,625 | 55,907 | Jan 16, 2024, 05:19 PM |
| Forbes William P | EVP, Chief Development Officer | Nov 17, 2023 | Buy | $1.09 | 25,000 | 27,250 | 79,000 | Nov 21, 2023, 12:19 PM |
| Forbes William P | EVP, Chief Development Officer | Nov 16, 2023 | Buy | $0.94 | 50,000 | 46,995 | 54,000 | Nov 20, 2023, 10:07 AM |
| Collard Craig A | Chief Executive Officer | Nov 16, 2023 | Buy | $0.92 | 150,000 | 137,970 | 186,496 | Nov 17, 2023, 12:37 PM |
| Duarte Ira | EVP, Chief Financial Officer | Nov 16, 2023 | Buy | $0.89 | 85,000 | 75,599 | 85,000 | Nov 17, 2023, 12:36 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jul 25, 2023 | Option Exercise | $1.51 | 14,743 | 22,262 | 53,198 | Oct 17, 2023, 07:57 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Oct 13, 2023 | Option Exercise | $0.72 | 860 | 619 | 54,822 | Oct 17, 2023, 07:57 PM |
| Collard Craig A | Chief Executive Officer | Aug 22, 2023 | Option Exercise | $1.65 | 692 | 1,142 | 36,496 | Aug 24, 2023, 04:09 PM |
| Morgan Adam | Director | Jul 21, 2023 | Buy | $1.37 | 2,486,744 | 3,406,839 | 6,986,744 | Jul 25, 2023, 04:22 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jul 13, 2023 | Option Exercise | $1.31 | 2,012 | 2,636 | 33,754 | Jul 17, 2023, 05:51 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jul 13, 2023 | Option Exercise | $1.31 | 860 | 1,127 | 25,310 | Jul 17, 2023, 05:51 PM |
| Collard Craig A | Chief Executive Officer | May 22, 2023 | Option Exercise | $1.45 | 691 | 1,002 | 37,188 | May 24, 2023, 05:04 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 13, 2023 | Option Exercise | $2.88 | 2,012 | 5,795 | 29,952 | Apr 17, 2023, 05:28 PM |
| POYHONEN JOHN | President & CCO | Apr 13, 2023 | Option Exercise | $2.88 | 2,012 | 5,795 | 46,648 | Apr 17, 2023, 05:27 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Apr 13, 2023 | Option Exercise | $2.88 | 860 | 2,477 | 23,685 | Apr 17, 2023, 05:27 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Apr 13, 2023 | Option Exercise | $2.88 | 1,417 | 4,081 | 28,330 | Apr 17, 2023, 05:26 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 13, 2023 | Option Exercise | $3.17 | 2,012 | 6,378 | 26,150 | Jan 17, 2023, 05:37 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Oct 31, 2022 | Option Exercise | $3.27 | 1,654 | 5,413 | 22,348 | Jan 17, 2023, 05:37 PM |
| Quart Barry D | Chief Executive Officer | Jan 13, 2023 | Option Exercise | $3.17 | 5,219 | 16,544 | 177,989 | Jan 17, 2023, 05:36 PM |
| Quart Barry D | Chief Executive Officer | Oct 31, 2022 | Option Exercise | $3.27 | 1,655 | 5,416 | 163,441 | Jan 17, 2023, 05:36 PM |
| POYHONEN JOHN | President & CCO | Jan 13, 2023 | Option Exercise | $3.17 | 2,012 | 6,378 | 42,846 | Jan 17, 2023, 05:36 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jan 13, 2023 | Option Exercise | $3.17 | 1,013 | 3,211 | 22,061 | Jan 17, 2023, 05:35 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jan 13, 2023 | Option Exercise | $3.17 | 2,012 | 6,378 | 23,933 | Jan 17, 2023, 05:34 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Oct 31, 2022 | Option Exercise | $3.27 | 1,655 | 5,416 | 20,131 | Jan 17, 2023, 05:34 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Oct 13, 2022 | Option Exercise | $3.76 | 2,012 | 7,565 | 20,694 | Oct 17, 2022, 04:38 PM |
| Quart Barry D | Chief Executive Officer | Oct 13, 2022 | Option Exercise | $3.76 | 5,219 | 19,623 | 161,786 | Oct 17, 2022, 04:38 PM |
| POYHONEN JOHN | President & CCO | Oct 13, 2022 | Option Exercise | $3.76 | 2,012 | 7,565 | 39,044 | Oct 17, 2022, 04:37 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Oct 13, 2022 | Option Exercise | $3.76 | 861 | 3,237 | 20,589 | Oct 17, 2022, 04:36 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Oct 13, 2022 | Option Exercise | $3.76 | 2,012 | 7,565 | 18,476 | Oct 17, 2022, 04:36 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jul 13, 2022 | Option Exercise | $3.01 | 2,012 | 6,056 | 16,892 | Jul 15, 2022, 04:58 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 29, 2022 | Option Exercise | $3.84 | 1,505 | 5,782 | 13,090 | Jul 15, 2022, 04:58 PM |
| Quart Barry D | Chief Executive Officer | Jul 13, 2022 | Option Exercise | $3.01 | 5,219 | 15,709 | 147,237 | Jul 15, 2022, 04:57 PM |
| Quart Barry D | Chief Executive Officer | Apr 29, 2022 | Option Exercise | $3.84 | 1,504 | 5,778 | 132,688 | Jul 15, 2022, 04:57 PM |
| POYHONEN JOHN | President & CCO | Jul 13, 2022 | Option Exercise | $3.01 | 2,012 | 6,056 | 35,242 | Jul 15, 2022, 04:56 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jul 13, 2022 | Option Exercise | $3.01 | 860 | 2,589 | 18,965 | Jul 15, 2022, 04:55 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jul 13, 2022 | Option Exercise | $3.01 | 2,012 | 6,056 | 14,674 | Jul 15, 2022, 04:55 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Apr 29, 2022 | Option Exercise | $3.84 | 1,504 | 5,778 | 12,376 | May 04, 2022, 07:01 PM |
| MANHARD KIMBERLY | EVP, Drug Development | May 03, 2022 | Sale | $4.76 | 1,504 | 7,154 | 10,872 | May 04, 2022, 07:01 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 13, 2022 | Option Exercise | $6.07 | 2,012 | 12,213 | 11,585 | Apr 15, 2022, 05:06 PM |
| Quart Barry D | Chief Executive Officer | Apr 13, 2022 | Option Exercise | $6.07 | 5,219 | 31,679 | 131,184 | Apr 15, 2022, 05:05 PM |
| POYHONEN JOHN | President & CCO | Apr 13, 2022 | Option Exercise | $6.07 | 2,012 | 12,213 | 31,440 | Apr 15, 2022, 05:04 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Apr 13, 2022 | Option Exercise | $6.07 | 860 | 5,220 | 17,340 | Apr 15, 2022, 05:03 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Apr 13, 2022 | Option Exercise | $6.07 | 2,012 | 12,213 | 10,872 | Apr 15, 2022, 05:03 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 13, 2022 | Option Exercise | $8.30 | 2,012 | 16,700 | 7,783 | Jan 14, 2022, 05:09 PM |
| Quart Barry D | Chief Executive Officer | Jan 13, 2022 | Option Exercise | $8.30 | 5,219 | 43,318 | 116,635 | Jan 14, 2022, 05:08 PM |
| POYHONEN JOHN | President & CCO | Jan 13, 2022 | Option Exercise | $8.30 | 2,012 | 16,700 | 27,638 | Jan 14, 2022, 05:07 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jan 13, 2022 | Option Exercise | $8.30 | 966 | 8,018 | 15,716 | Jan 14, 2022, 05:06 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jan 13, 2022 | Option Exercise | $8.30 | 2,012 | 16,700 | 7,070 | Jan 14, 2022, 05:05 PM |
| POYHONEN JOHN | President & CCO | Oct 29, 2021 | Option Exercise | $9.36 | 817 | 7,646 | 23,836 | Dec 23, 2021, 06:59 PM |
| Christian Waage | Director | Dec 21, 2021 | Sale | $9.73 | 300 | 2,920 | 3,200 | Dec 23, 2021, 06:58 PM |
| Johnson Craig A | Director | Dec 21, 2021 | Sale | $9.73 | 250 | 2,432 | 2,840 | Dec 23, 2021, 06:57 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Oct 13, 2021 | Option Exercise | $10.55 | 433 | 4,568 | 3,981 | Oct 15, 2021, 04:26 PM |
| Quart Barry D | Chief Executive Officer | Oct 13, 2021 | Option Exercise | $10.55 | 963 | 10,160 | 102,086 | Oct 15, 2021, 04:25 PM |
| POYHONEN JOHN | President & CCO | Oct 13, 2021 | Option Exercise | $10.55 | 433 | 4,568 | 23,019 | Oct 15, 2021, 04:24 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Oct 13, 2021 | Option Exercise | $10.55 | 191 | 2,015 | 14,197 | Oct 15, 2021, 04:23 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Oct 13, 2021 | Option Exercise | $10.55 | 433 | 4,568 | 3,268 | Oct 15, 2021, 04:22 PM |
| Christian Waage | Director | Sep 21, 2021 | Sale | $12.31 | 300 | 3,692 | 3,500 | Sep 23, 2021, 04:30 PM |
| Johnson Craig A | Director | Sep 21, 2021 | Sale | $12.30 | 250 | 3,074 | 3,090 | Sep 23, 2021, 04:29 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jul 13, 2021 | Option Exercise | $13.48 | 433 | 5,837 | 3,164 | Jul 15, 2021, 04:52 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 30, 2021 | Option Exercise | $13.90 | 1,530 | 21,263 | 2,347 | Jul 15, 2021, 04:52 PM |
| Quart Barry D | Chief Executive Officer | Jul 13, 2021 | Option Exercise | $13.48 | 963 | 12,981 | 99,403 | Jul 15, 2021, 04:50 PM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2021 | Option Exercise | $13.90 | 1,529 | 21,249 | 96,721 | Jul 15, 2021, 04:50 PM |
| POYHONEN JOHN | President & CCO | Jul 13, 2021 | Option Exercise | $13.48 | 433 | 5,837 | 22,202 | Jul 15, 2021, 04:49 PM |
| POYHONEN JOHN | President & CCO | Apr 30, 2021 | Option Exercise | $13.90 | 971 | 13,494 | 21,385 | Jul 15, 2021, 04:49 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jul 13, 2021 | Option Exercise | $13.48 | 191 | 2,575 | 13,836 | Jul 15, 2021, 04:48 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Apr 30, 2021 | Option Exercise | $13.90 | 1,530 | 21,263 | 13,475 | Jul 15, 2021, 04:48 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jul 13, 2021 | Option Exercise | $13.48 | 433 | 5,837 | 2,451 | Jul 15, 2021, 04:47 PM |
| Johnson Craig A | Director | Jun 21, 2021 | Sale | $15.20 | 250 | 3,801 | 3,340 | Jun 22, 2021, 05:05 PM |
| Christian Waage | Director | Apr 15, 2021 | Sale | $17.51 | 300 | 5,254 | 4,100 | Apr 16, 2021, 08:59 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 13, 2021 | Option Exercise | $16.66 | 433 | 7,214 | 817 | Apr 15, 2021, 04:55 PM |
| Quart Barry D | Chief Executive Officer | Apr 13, 2021 | Option Exercise | $16.66 | 963 | 16,044 | 95,192 | Apr 15, 2021, 04:54 PM |
| POYHONEN JOHN | President & CCO | Apr 13, 2021 | Option Exercise | $16.66 | 433 | 7,214 | 20,414 | Apr 15, 2021, 04:53 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Apr 13, 2021 | Option Exercise | $16.66 | 191 | 3,182 | 11,945 | Apr 15, 2021, 04:52 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Apr 13, 2021 | Option Exercise | $16.66 | 433 | 7,214 | 1,634 | Apr 15, 2021, 04:51 PM |
| Johnson Craig A | Director | Apr 06, 2021 | Sale | $17.22 | 250 | 4,305 | 3,590 | Apr 07, 2021, 05:04 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 13, 2021 | Option Exercise | $18.16 | 423 | 7,682 | 827 | Jan 15, 2021, 04:30 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 14, 2021 | Sale | $18.09 | 827 | 14,960 | 0 | Jan 15, 2021, 04:30 PM |
| Quart Barry D | Chief Executive Officer | Jan 13, 2021 | Option Exercise | $18.16 | 963 | 17,488 | 91,909 | Jan 15, 2021, 04:29 PM |
| POYHONEN JOHN | President & CCO | Jan 13, 2021 | Option Exercise | $18.16 | 433 | 7,863 | 19,597 | Jan 15, 2021, 04:27 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jan 13, 2021 | Option Exercise | $18.16 | 227 | 4,122 | 11,584 | Jan 15, 2021, 04:26 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jan 13, 2021 | Option Exercise | $18.16 | 433 | 7,863 | 817 | Jan 15, 2021, 04:25 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 08, 2021 | Sale | $19.66 | 3,571 | 70,219 | 0 | Jan 08, 2021, 06:07 PM |
| POYHONEN JOHN | President & CCO | Oct 30, 2020 | Option Exercise | $11.65 | 637 | 7,423 | 18,780 | Dec 23, 2020, 04:24 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Dec 22, 2020 | Option Exercise | $13.00 | 10,000 | 130,000 | 10,000 | Dec 23, 2020, 04:23 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Dec 22, 2020 | Sale | $20.00 | 10,000 | 200,000 | 0 | Dec 23, 2020, 04:23 PM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2020 | Option Exercise | $12.12 | 1,158 | 14,036 | 89,226 | Oct 15, 2020, 04:23 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Apr 30, 2020 | Option Exercise | $12.12 | 1,158 | 14,036 | 1,158 | May 01, 2020, 06:48 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | May 01, 2020 | Sale | $13.97 | 1,158 | 16,176 | 0 | May 01, 2020, 06:48 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Nov 29, 2019 | Option Exercise | $13.00 | 24,000 | 312,000 | 24,000 | Dec 03, 2019, 06:30 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Nov 29, 2019 | Sale | $26.00 | 24,000 | 624,000 | 0 | Dec 03, 2019, 06:30 PM |
| TANG KEVIN C | Director | Oct 04, 2019 | Buy | $17.50 | 285,714 | 4,999,995 | 5,799,810 | Oct 07, 2019, 05:18 PM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2019 | Option Exercise | $18.43 | 806 | 14,853 | 90,081 | Oct 04, 2019, 07:58 PM |
| Quart Barry D | Chief Executive Officer | Oct 03, 2019 | Buy | $17.50 | 4,571 | 79,993 | 94,652 | Oct 04, 2019, 07:58 PM |
| POYHONEN JOHN | EVP, Chief Commercial Officer | Oct 03, 2019 | Buy | $17.50 | 5,143 | 90,003 | 18,143 | Oct 04, 2019, 07:56 PM |
| POYHONEN JOHN | Director | May 22, 2019 | Buy | $17.55 | 3,000 | 52,650 | 13,000 | May 23, 2019, 08:39 AM |
| Christian Waage | Director | May 15, 2019 | Buy | $18.04 | 1,400 | 25,262 | 1,400 | May 16, 2019, 08:44 AM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Apr 30, 2019 | Option Exercise | $18.43 | 1,109 | 20,437 | 1,109 | May 02, 2019, 08:40 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | May 01, 2019 | Sale | $18.86 | 1,109 | 20,918 | 0 | May 02, 2019, 08:40 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Oct 31, 2018 | Option Exercise | $23.60 | 494 | 11,656 | 494 | Nov 02, 2018, 09:17 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Nov 02, 2018 | Sale | $30.62 | 494 | 15,125 | 0 | Nov 02, 2018, 09:17 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Oct 01, 2018 | Option Exercise | $13.00 | 6,000 | 78,000 | 6,000 | Oct 02, 2018, 09:12 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Oct 01, 2018 | Sale | $32.07 | 6,000 | 192,433 | 0 | Oct 02, 2018, 09:12 PM |
| Quart Barry D | Chief Executive Officer | Sep 14, 2018 | Option Exercise | $7.20 | 19,675 | 141,660 | 89,275 | Sep 14, 2018, 11:41 AM |
| TANG KEVIN C | Director | Sep 12, 2018 | Sale | $35.75 | 2,695,000 | 96,346,250 | 5,830,215 | Sep 12, 2018, 12:28 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Jul 02, 2018 | Option Exercise | $13.00 | 6,000 | 78,000 | 6,000 | Jul 03, 2018, 09:05 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Jul 02, 2018 | Sale | $37.53 | 6,000 | 225,179 | 100 | Jul 03, 2018, 09:05 PM |
| HOFFMAN ROBERT | CFO & SVP, Finance | Apr 30, 2018 | Option Exercise | $13.22 | 744 | 9,834 | 1,280 | Jul 03, 2018, 09:03 PM |
| HOFFMAN ROBERT | CFO & SVP, Finance | Jul 02, 2018 | Option Exercise | $15.30 | 30,000 | 459,000 | 31,280 | Jul 03, 2018, 09:03 PM |
| HOFFMAN ROBERT | CFO & SVP, Finance | Jul 02, 2018 | Sale | $38.17 | 30,000 | 1,145,230 | 2,340 | Jul 03, 2018, 09:03 PM |
| Rosen Robert | President | Jul 02, 2018 | Option Exercise | $7.20 | 95,531 | 687,823 | 98,171 | Jul 03, 2018, 09:01 PM |
| Rosen Robert | President | Jun 29, 2018 | Option Exercise | $7.20 | 129,469 | 932,177 | 132,109 | Jul 03, 2018, 09:01 PM |
| Rosen Robert | President | Jun 29, 2018 | Sale | $39.59 | 129,469 | 5,125,135 | 56,448 | Jul 03, 2018, 09:01 PM |
| Rosen Robert | President | Jul 02, 2018 | Sale | $38.15 | 95,531 | 3,644,683 | 6,040 | Jul 03, 2018, 09:01 PM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2018 | Option Exercise | $13.22 | 1,607 | 21,241 | 69,600 | Jun 22, 2018, 09:35 PM |
| Quart Barry D | Chief Executive Officer | Jun 21, 2018 | Option Exercise | $9.05 | 50,000 | 452,500 | 119,600 | Jun 22, 2018, 09:35 PM |
| Quart Barry D | Chief Executive Officer | Jun 21, 2018 | Sale | $39.05 | 50,000 | 1,952,500 | 69,600 | Jun 22, 2018, 09:35 PM |
| TANG KEVIN C | Director | Mar 29, 2018 | Buy | $26.00 | 192,308 | 5,000,008 | 8,525,215 | Apr 02, 2018, 04:01 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Mar 19, 2018 | Option Exercise | $13.00 | 18,000 | 234,000 | 18,000 | Mar 19, 2018, 07:24 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Mar 19, 2018 | Sale | $30.00 | 18,000 | 540,000 | 0 | Mar 19, 2018, 07:24 PM |
| Quart Barry D | Chief Executive Officer | Mar 19, 2018 | Option Exercise | $7.20 | 100,000 | 720,000 | 167,993 | Mar 19, 2018, 07:22 PM |
| Quart Barry D | Chief Executive Officer | Mar 19, 2018 | Sale | $29.75 | 100,000 | 2,975,000 | 67,993 | Mar 19, 2018, 07:22 PM |
| Quart Barry D | Chief Executive Officer | Mar 14, 2018 | Option Exercise | $7.20 | 100,000 | 720,000 | 167,993 | Mar 16, 2018, 09:00 PM |
| Quart Barry D | Chief Executive Officer | Mar 14, 2018 | Sale | $24.75 | 100,000 | 2,475,000 | 67,993 | Mar 16, 2018, 09:00 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Jan 10, 2018 | Option Exercise | $13.00 | 7,584 | 98,592 | 7,584 | Jan 12, 2018, 04:21 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Jan 10, 2018 | Sale | $20.00 | 7,584 | 151,680 | 0 | Jan 12, 2018, 04:21 PM |
| Quart Barry D | Chief Executive Officer | Apr 28, 2017 | Option Exercise | $12.62 | 1,684 | 21,256 | 67,993 | Dec 20, 2017, 04:15 PM |
| HOFFMAN ROBERT | CFO & SVP, Finance | Oct 31, 2017 | Option Exercise | $13.05 | 536 | 6,993 | 536 | Dec 20, 2017, 04:13 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Apr 24, 2017 | Option Exercise | $8.99 | 21,542 | 193,643 | 21,542 | Apr 24, 2017, 08:58 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Apr 24, 2017 | Sale | $15.33 | 21,542 | 330,263 | 0 | Apr 24, 2017, 08:58 PM |
| POYHONEN JOHN | Director | Jan 19, 2017 | Buy | $12.20 | 10,000 | 122,000 | 10,000 | Jan 23, 2017, 04:29 PM |
| TANG KEVIN C | Director | Jan 19, 2017 | Buy | $12.20 | 2,459,016 | 29,999,995 | 8,332,907 | Jan 23, 2017, 04:03 PM |
| Drazba Brian G. | VP, Finance & CFO | Oct 31, 2016 | Option Exercise | $12.62 | 538 | 6,791 | 3,798 | Dec 23, 2016, 04:03 PM |
| Drazba Brian G. | VP, Finance & CFO | Apr 29, 2016 | Option Exercise | $18.22 | 577 | 10,515 | 3,260 | Dec 23, 2016, 04:03 PM |
| Rosen Robert | President & CCO | Aug 10, 2016 | Option Exercise | $7.20 | 100,000 | 720,000 | 102,640 | Aug 12, 2016, 05:14 PM |
| Rosen Robert | President & CCO | Aug 10, 2016 | Sale | $23.30 | 100,000 | 2,329,895 | 15,040 | Aug 12, 2016, 05:14 PM |
| Quart Barry D | Chief Executive Officer | Apr 29, 2016 | Option Exercise | $18.22 | 837 | 15,253 | 61,679 | Jul 20, 2016, 08:50 AM |
| Quart Barry D | Chief Executive Officer | Jul 19, 2016 | Option Exercise | $7.20 | 4,630 | 33,336 | 66,309 | Jul 20, 2016, 08:50 AM |
| TANG KEVIN C | Director | Jun 16, 2016 | Option Exercise | $18.47 | 243,639 | 4,500,012 | 5,873,891 | Jun 20, 2016, 08:01 PM |
| TANG KEVIN C | Director | Jun 16, 2016 | Option Exercise | $3.60 | 1,250,000 | 4,500,000 | 6,117,530 | Jun 20, 2016, 08:01 PM |
| Rosen Robert | President | Apr 19, 2016 | Option Exercise | $7.20 | 176,328 | 1,269,562 | 178,968 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 21, 2016 | Option Exercise | $7.20 | 19,662 | 141,566 | 22,302 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 20, 2016 | Option Exercise | $7.20 | 4,010 | 28,872 | 6,650 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 21, 2016 | Sale | $22.15 | 19,662 | 435,433 | 2,640 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 20, 2016 | Sale | $22.19 | 4,010 | 88,967 | 2,640 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 19, 2016 | Sale | $23.38 | 176,328 | 4,122,022 | 118,043 | Apr 21, 2016, 09:27 PM |
| Marshall Paul | SVP, Technical Operations | Mar 21, 2016 | Option Exercise | $9.05 | 1,100 | 9,955 | 2,200 | Mar 23, 2016, 03:07 PM |
| Quart Barry D | Chief Executive Officer | Mar 02, 2016 | Option Exercise | $7.20 | 3,472 | 24,998 | 60,842 | Mar 03, 2016, 08:01 AM |
| Marshall Paul | SVP, Technical Operations | Dec 29, 2015 | Option Exercise | $9.05 | 1,100 | 9,955 | 1,100 | Dec 30, 2015, 05:14 PM |
| Quart Barry D | Chief Executive Officer | Dec 28, 2015 | Option Exercise | $7.20 | 2,315 | 16,668 | 82,370 | Dec 30, 2015, 05:13 PM |
| Drazba Brian G. | VP, Finance & CFO | Apr 30, 2015 | Option Exercise | $7.60 | 1,151 | 8,746 | 1,969 | Dec 24, 2015, 12:29 PM |
| Drazba Brian G. | VP, Finance & CFO | Oct 30, 2015 | Option Exercise | $9.36 | 714 | 6,682 | 2,683 | Dec 24, 2015, 12:29 PM |
| Quart Barry D | Chief Executive Officer | Oct 14, 2015 | Option Exercise | $7.20 | 10,000 | 72,000 | 80,055 | Oct 15, 2015, 08:02 AM |
| Quart Barry D | Chief Executive Officer | Sep 29, 2015 | Option Exercise | $7.20 | 14,306 | 103,003 | 70,055 | Sep 30, 2015, 08:51 AM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2015 | Option Exercise | $7.60 | 2,881 | 21,896 | 45,749 | Aug 19, 2015, 04:39 PM |
| Quart Barry D | Chief Executive Officer | Aug 18, 2015 | Option Exercise | $7.20 | 10,000 | 72,000 | 55,749 | Aug 19, 2015, 04:39 PM |
| TANG KEVIN C | Director | Jun 10, 2015 | Buy | $24.75 | 121,212 | 2,999,997 | 4,867,530 | Jun 12, 2015, 04:06 PM |
| MANHARD KIMBERLY | Director | Jun 02, 2015 | Option Exercise | $8.80 | 10,500 | 92,400 | 10,500 | Jun 03, 2015, 06:46 PM |
| MANHARD KIMBERLY | Director | Jun 01, 2015 | Option Exercise | $9.05 | 2,708 | 24,507 | 2,708 | Jun 03, 2015, 06:46 PM |
| MANHARD KIMBERLY | Director | Jun 02, 2015 | Sale | $23.58 | 10,500 | 247,590 | 0 | Jun 03, 2015, 06:46 PM |
| MANHARD KIMBERLY | Director | Jun 01, 2015 | Sale | $21.17 | 2,708 | 57,328 | 0 | Jun 03, 2015, 06:46 PM |
| TANG KEVIN C | Director | Jun 02, 2015 | Buy | $23.84 | 32,395 | 772,294 | 4,746,318 | Jun 02, 2015, 04:01 PM |
| TANG KEVIN C | Director | Jun 01, 2015 | Buy | $19.30 | 2,380 | 45,934 | 4,713,923 | Jun 02, 2015, 04:01 PM |
| TANG KEVIN C | Director | May 29, 2015 | Buy | $19.74 | 115,225 | 2,274,058 | 4,711,543 | Jun 02, 2015, 04:01 PM |
| Marshall Paul | SVP, Technical Operations | Mar 05, 2015 | Option Exercise | $9.40 | 70,000 | 658,000 | 70,000 | Mar 09, 2015, 07:02 PM |
| Marshall Paul | SVP, Technical Operations | Mar 05, 2015 | Sale | $14.69 | 70,000 | 1,028,000 | 20,000 | Mar 09, 2015, 07:02 PM |
| Quart Barry D | Chief Executive Officer | Mar 02, 2015 | Sale | $13.07 | 10,000 | 130,727 | 42,868 | Mar 04, 2015, 06:52 PM |
| Quart Barry D | Chief Executive Officer | Oct 31, 2014 | Option Exercise | $7.50 | 1,941 | 14,552 | 63,796 | Dec 15, 2014, 09:03 PM |
| Drazba Brian G. | VP, Finance & CFO | Oct 31, 2014 | Option Exercise | $7.50 | 818 | 6,133 | 818 | Dec 15, 2014, 08:58 PM |
| DAVIS STEPHEN | Director | Sep 26, 2014 | Option Exercise | $8.44 | 102,634 | 866,231 | 20,076 | Sep 30, 2014, 06:41 PM |
| DAVIS STEPHEN | Director | Sep 26, 2014 | Option Exercise | $7.20 | 120,313 | 866,254 | 122,710 | Sep 30, 2014, 06:41 PM |
| TANG KEVIN C | Director | Jun 25, 2014 | Buy | $11.75 | 510,638 | 5,999,997 | 4,596,318 | Jun 27, 2014, 04:01 PM |
| Quart Barry D | Chief Executive Officer | Jun 25, 2014 | Buy | $11.75 | 10,000 | 117,500 | 61,855 | Jun 26, 2014, 06:48 PM |
| TANG KEVIN C | Director | Nov 20, 2013 | Option Exercise | $0.40 | 17,500,000 | 7,000,000 | 81,713,600 | Nov 22, 2013, 05:02 PM |
| Quart Barry D | Chief Executive Officer | Nov 20, 2013 | Buy | $0.40 | 1,000,000 | 400,000 | 1,037,100 | Nov 21, 2013, 03:57 PM |
| Whelan John | CFO | Jul 18, 2013 | Option Exercise | $0.26 | 254,088 | 66,063 | 254,088 | Jul 19, 2013, 07:21 PM |
| SPCH, LLLP | 10% Owner | Jul 25, 2012 | Buy | $0.52 | 38,095,238 | 19,999,999 | 38,095,238 | Sep 12, 2012, 05:05 PM |
| TANG KEVIN C | Director | Jul 25, 2012 | Option Exercise | $0.52 | 9,523,810 | 5,000,000 | 69,960,316 | Jul 27, 2012, 07:16 PM |
| TANG KEVIN C | Director | Jun 29, 2011 | Option Exercise | $0.15 | 50,000,000 | 7,500,000 | 60,436,506 | Jul 01, 2011, 04:22 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Duarte Ira | EVP, Chief Financial Officer | 04/19/2024 | 2,962 |
| Peraza Lisa | VP, Chief Accounting Officer | 01/13/2024 | 1,625 |
| Forbes William P | EVP, Chief Development Officer | 11/17/2023 | 27,250 |
| Forbes William P | EVP, Chief Development Officer | 11/16/2023 | 46,995 |
| Collard Craig A | Chief Executive Officer | 11/16/2023 | 137,970 |
| Duarte Ira | EVP, Chief Financial Officer | 11/16/2023 | 75,599 |
| Peraza Lisa | VP, Chief Accounting Officer | 07/25/2023 | 22,262 |
| Peraza Lisa | VP, Chief Accounting Officer | 10/13/2023 | 619 |
| Collard Craig A | Chief Executive Officer | 08/22/2023 | 1,142 |
| Morgan Adam | Director | 07/21/2023 | 3,406,839 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 07/13/2023 | 2,636 |
| Peraza Lisa | VP, Chief Accounting Officer | 07/13/2023 | 1,127 |
| Collard Craig A | Chief Executive Officer | 05/22/2023 | 1,002 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/13/2023 | 5,795 |
| POYHONEN JOHN | President & CCO | 04/13/2023 | 5,795 |
| Peraza Lisa | VP, Chief Accounting Officer | 04/13/2023 | 2,477 |
| MANHARD KIMBERLY | EVP, Drug Development | 04/13/2023 | 4,081 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/13/2023 | 6,378 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 10/31/2022 | 5,413 |
| Quart Barry D | Chief Executive Officer | 01/13/2023 | 16,544 |
| Quart Barry D | Chief Executive Officer | 10/31/2022 | 5,416 |
| POYHONEN JOHN | President & CCO | 01/13/2023 | 6,378 |
| Peraza Lisa | VP, Chief Accounting Officer | 01/13/2023 | 3,211 |
| MANHARD KIMBERLY | EVP, Drug Development | 01/13/2023 | 6,378 |
| MANHARD KIMBERLY | EVP, Drug Development | 10/31/2022 | 5,416 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 10/13/2022 | 7,565 |
| Quart Barry D | Chief Executive Officer | 10/13/2022 | 19,623 |
| POYHONEN JOHN | President & CCO | 10/13/2022 | 7,565 |
| Peraza Lisa | VP, Chief Accounting Officer | 10/13/2022 | 3,237 |
| MANHARD KIMBERLY | EVP, Drug Development | 10/13/2022 | 7,565 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 07/13/2022 | 6,056 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/29/2022 | 5,782 |
| Quart Barry D | Chief Executive Officer | 07/13/2022 | 15,709 |
| Quart Barry D | Chief Executive Officer | 04/29/2022 | 5,778 |
| POYHONEN JOHN | President & CCO | 07/13/2022 | 6,056 |
| Peraza Lisa | VP, Chief Accounting Officer | 07/13/2022 | 2,589 |
| MANHARD KIMBERLY | EVP, Drug Development | 07/13/2022 | 6,056 |
| MANHARD KIMBERLY | EVP, Drug Development | 04/29/2022 | 5,778 |
| MANHARD KIMBERLY | EVP, Drug Development | 05/03/2022 | 7,154 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/13/2022 | 12,213 |
| Quart Barry D | Chief Executive Officer | 04/13/2022 | 31,679 |
| POYHONEN JOHN | President & CCO | 04/13/2022 | 12,213 |
| Peraza Lisa | VP, Chief Accounting Officer | 04/13/2022 | 5,220 |
| MANHARD KIMBERLY | EVP, Drug Development | 04/13/2022 | 12,213 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/13/2022 | 16,700 |
| Quart Barry D | Chief Executive Officer | 01/13/2022 | 43,318 |
| POYHONEN JOHN | President & CCO | 01/13/2022 | 16,700 |
| Peraza Lisa | VP, Chief Accounting Officer | 01/13/2022 | 8,018 |
| MANHARD KIMBERLY | EVP, Drug Development | 01/13/2022 | 16,700 |
| POYHONEN JOHN | President & CCO | 10/29/2021 | 7,646 |
| Christian Waage | Director | 12/21/2021 | 2,920 |
| Johnson Craig A | Director | 12/21/2021 | 2,432 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 10/13/2021 | 4,568 |
| Quart Barry D | Chief Executive Officer | 10/13/2021 | 10,160 |
| POYHONEN JOHN | President & CCO | 10/13/2021 | 4,568 |
| Peraza Lisa | VP, Chief Accounting Officer | 10/13/2021 | 2,015 |
| MANHARD KIMBERLY | EVP, Drug Development | 10/13/2021 | 4,568 |
| Christian Waage | Director | 09/21/2021 | 3,692 |
| Johnson Craig A | Director | 09/21/2021 | 3,074 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 07/13/2021 | 5,837 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/30/2021 | 21,263 |
| Quart Barry D | Chief Executive Officer | 07/13/2021 | 12,981 |
| Quart Barry D | Chief Executive Officer | 04/30/2021 | 21,249 |
| POYHONEN JOHN | President & CCO | 07/13/2021 | 5,837 |
| POYHONEN JOHN | President & CCO | 04/30/2021 | 13,494 |
| Peraza Lisa | VP, Chief Accounting Officer | 07/13/2021 | 2,575 |
| Peraza Lisa | VP, Chief Accounting Officer | 04/30/2021 | 21,263 |
| MANHARD KIMBERLY | EVP, Drug Development | 07/13/2021 | 5,837 |
| Johnson Craig A | Director | 06/21/2021 | 3,801 |
| Christian Waage | Director | 04/15/2021 | 5,254 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/13/2021 | 7,214 |
| Quart Barry D | Chief Executive Officer | 04/13/2021 | 16,044 |
| POYHONEN JOHN | President & CCO | 04/13/2021 | 7,214 |
| Peraza Lisa | VP, Chief Accounting Officer | 04/13/2021 | 3,182 |
| MANHARD KIMBERLY | EVP, Drug Development | 04/13/2021 | 7,214 |
| Johnson Craig A | Director | 04/06/2021 | 4,305 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/13/2021 | 7,682 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/14/2021 | 14,960 |
| Quart Barry D | Chief Executive Officer | 01/13/2021 | 17,488 |
| POYHONEN JOHN | President & CCO | 01/13/2021 | 7,863 |
| Peraza Lisa | VP, Chief Accounting Officer | 01/13/2021 | 4,122 |
| MANHARD KIMBERLY | EVP, Drug Development | 01/13/2021 | 7,863 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/08/2021 | 70,219 |
| POYHONEN JOHN | President & CCO | 10/30/2020 | 7,423 |
| MANHARD KIMBERLY | EVP, Drug Development | 12/22/2020 | 130,000 |
| MANHARD KIMBERLY | EVP, Drug Development | 12/22/2020 | 200,000 |
| Quart Barry D | Chief Executive Officer | 04/30/2020 | 14,036 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 04/30/2020 | 14,036 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 05/01/2020 | 16,176 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 11/29/2019 | 312,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 11/29/2019 | 624,000 |
| TANG KEVIN C | Director | 10/04/2019 | 4,999,995 |
| Quart Barry D | Chief Executive Officer | 04/30/2019 | 14,853 |
| Quart Barry D | Chief Executive Officer | 10/03/2019 | 79,993 |
| POYHONEN JOHN | EVP, Chief Commercial Officer | 10/03/2019 | 90,003 |
| POYHONEN JOHN | Director | 05/22/2019 | 52,650 |
| Christian Waage | Director | 05/15/2019 | 25,262 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 04/30/2019 | 20,437 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 05/01/2019 | 20,918 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 10/31/2018 | 11,656 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 11/02/2018 | 15,125 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 10/01/2018 | 78,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 10/01/2018 | 192,433 |
| Quart Barry D | Chief Executive Officer | 09/14/2018 | 141,660 |
| TANG KEVIN C | Director | 09/12/2018 | 96,346,250 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 07/02/2018 | 78,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 07/02/2018 | 225,179 |
| HOFFMAN ROBERT | CFO & SVP, Finance | 04/30/2018 | 9,834 |
| HOFFMAN ROBERT | CFO & SVP, Finance | 07/02/2018 | 459,000 |
| HOFFMAN ROBERT | CFO & SVP, Finance | 07/02/2018 | 1,145,230 |
| Rosen Robert | President | 07/02/2018 | 687,823 |
| Rosen Robert | President | 06/29/2018 | 932,177 |
| Rosen Robert | President | 06/29/2018 | 5,125,135 |
| Rosen Robert | President | 07/02/2018 | 3,644,683 |
| Quart Barry D | Chief Executive Officer | 04/30/2018 | 21,241 |
| Quart Barry D | Chief Executive Officer | 06/21/2018 | 452,500 |
| Quart Barry D | Chief Executive Officer | 06/21/2018 | 1,952,500 |
| TANG KEVIN C | Director | 03/29/2018 | 5,000,008 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 03/19/2018 | 234,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 03/19/2018 | 540,000 |
| Quart Barry D | Chief Executive Officer | 03/19/2018 | 720,000 |
| Quart Barry D | Chief Executive Officer | 03/19/2018 | 2,975,000 |
| Quart Barry D | Chief Executive Officer | 03/14/2018 | 720,000 |
| Quart Barry D | Chief Executive Officer | 03/14/2018 | 2,475,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 01/10/2018 | 98,592 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 01/10/2018 | 151,680 |
| Quart Barry D | Chief Executive Officer | 04/28/2017 | 21,256 |
| HOFFMAN ROBERT | CFO & SVP, Finance | 10/31/2017 | 6,993 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 04/24/2017 | 193,643 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 04/24/2017 | 330,263 |
| POYHONEN JOHN | Director | 01/19/2017 | 122,000 |
| TANG KEVIN C | Director | 01/19/2017 | 29,999,995 |
| Drazba Brian G. | VP, Finance & CFO | 10/31/2016 | 6,791 |
| Drazba Brian G. | VP, Finance & CFO | 04/29/2016 | 10,515 |
| Rosen Robert | President & CCO | 08/10/2016 | 720,000 |
| Rosen Robert | President & CCO | 08/10/2016 | 2,329,895 |
| Quart Barry D | Chief Executive Officer | 04/29/2016 | 15,253 |
| Quart Barry D | Chief Executive Officer | 07/19/2016 | 33,336 |
| TANG KEVIN C | Director | 06/16/2016 | 4,500,012 |
| TANG KEVIN C | Director | 06/16/2016 | 4,500,000 |
| Rosen Robert | President | 04/19/2016 | 1,269,562 |
| Rosen Robert | President | 04/21/2016 | 141,566 |
| Rosen Robert | President | 04/20/2016 | 28,872 |
| Rosen Robert | President | 04/21/2016 | 435,433 |
| Rosen Robert | President | 04/20/2016 | 88,967 |
| Rosen Robert | President | 04/19/2016 | 4,122,022 |
| Marshall Paul | SVP, Technical Operations | 03/21/2016 | 9,955 |
| Quart Barry D | Chief Executive Officer | 03/02/2016 | 24,998 |
| Marshall Paul | SVP, Technical Operations | 12/29/2015 | 9,955 |
| Quart Barry D | Chief Executive Officer | 12/28/2015 | 16,668 |
| Drazba Brian G. | VP, Finance & CFO | 04/30/2015 | 8,746 |
| Drazba Brian G. | VP, Finance & CFO | 10/30/2015 | 6,682 |
| Quart Barry D | Chief Executive Officer | 10/14/2015 | 72,000 |
| Quart Barry D | Chief Executive Officer | 09/29/2015 | 103,003 |
| Quart Barry D | Chief Executive Officer | 04/30/2015 | 21,896 |
| Quart Barry D | Chief Executive Officer | 08/18/2015 | 72,000 |
| TANG KEVIN C | Director | 06/10/2015 | 2,999,997 |
| MANHARD KIMBERLY | Director | 06/02/2015 | 92,400 |
| MANHARD KIMBERLY | Director | 06/01/2015 | 24,507 |
| MANHARD KIMBERLY | Director | 06/02/2015 | 247,590 |
| MANHARD KIMBERLY | Director | 06/01/2015 | 57,328 |
| TANG KEVIN C | Director | 06/02/2015 | 772,294 |
| TANG KEVIN C | Director | 06/01/2015 | 45,934 |
| TANG KEVIN C | Director | 05/29/2015 | 2,274,058 |
| Marshall Paul | SVP, Technical Operations | 03/05/2015 | 658,000 |
| Marshall Paul | SVP, Technical Operations | 03/05/2015 | 1,028,000 |
| Quart Barry D | Chief Executive Officer | 03/02/2015 | 130,727 |
| Quart Barry D | Chief Executive Officer | 10/31/2014 | 14,552 |
| Drazba Brian G. | VP, Finance & CFO | 10/31/2014 | 6,133 |
| DAVIS STEPHEN | Director | 09/26/2014 | 866,231 |
| DAVIS STEPHEN | Director | 09/26/2014 | 866,254 |
| TANG KEVIN C | Director | 06/25/2014 | 5,999,997 |
| Quart Barry D | Chief Executive Officer | 06/25/2014 | 117,500 |
| TANG KEVIN C | Director | 11/20/2013 | 7,000,000 |
| Quart Barry D | Chief Executive Officer | 11/20/2013 | 400,000 |
| Whelan John | CFO | 07/18/2013 | 66,063 |
| SPCH, LLLP | 10% Owner | 07/25/2012 | 19,999,999 |
| TANG KEVIN C | Director | 07/25/2012 | 5,000,000 |
| TANG KEVIN C | Director | 06/29/2011 | 7,500,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN HERON THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10,111,550 | 0.51% | 70.56% | Other |
| BLACKROCK INC. | 7,286,028 | 0.00047% | 1.73% | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,910,011 | 0.02% | No change | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 2,796,119 | 0.00072% | 6.53% | Other |
| D. E. SHAW & CO., INC. | 2,695,046 | 0.00639% | 108.76% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 2,406,486 | 0.01% | 27.78% | Other |
| NEXPOINT ASSET MANAGEMENT, L.P. | 475,750 | 0.2% | No change | Event Driven, Value |
| AQR CAPITAL MANAGEMENT LLC | 38,897 | 0.00018% | 5.54% | Other |
CHANGE IN SHARES OUTSTANDING FOR HERON THERAPEUTICS INC
STOCK BUYBACKS FOR HERON THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
4.35%
1Q
06/30/2023
26.38%
2Q
03/31/2023
26.88%
3Q
12/31/2022
27.00%
4Q
09/30/2022
35.41%
5Q
06/30/2022
47.75%
6Q
03/31/2022
48.15%
7Q
12/31/2021
48.31%
8Q
09/30/2021
48.47%
9Q
06/30/2021
53.67%
10Q
03/31/2021
65.56%
11Q
12/31/2020
66.11%
12Q
09/30/2020
66.54%
13Q
06/30/2020
66.72%
14Q
03/31/2020
67.35%
15Q
12/31/2019
69.63%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR HERON THERAPEUTICS INC
LOADING...